Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.02 – $0.11
30% from low
Exchange
OTC Link
CS
Borrow rate
0.33%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | −$100 | $0 | $1.7M | $0 | $0 | $70.0K | $0 | $0 |
| Cost of revenue | $34.2K | $60.6K | $0 | $61.5K | $12.8K | $0 | $0 | $0 |
| Gross profit | −$34.3K | −$60.6K | $1.7M | −$61.5K | −$12.8K | $70.0K | $0 | $0 |
| Gross margin | 34289.0% | — | 100.0% | — | — | 100.0% | — | — |
| R&D | $815.0K | $1.4M | $4.3M | $3.7M | $756.9K | $61.1K | $0 | $4.36B |
| Operating income | −$3.0M | −$4.3M | −$7.6M | −$9.1M | −$9.7M | −$6.6M | −$3.58B | −$3.2M |
| EBITDA | −$678.5K | −$5.8M | −$7.6M | −$9.1M | −$5.6M | −$7.2M | −$3.5M | $198.05B |
| Net income | −$2.7M | −$7.4M | −$11.5M | −$11.4M | $17.8M | −$7.9M | −$4.52B | $249.3M |
| Net margin | 2737000.0% | — | -660.6% | — | — | -11290.1% | — | — |
| EPS (diluted) | -0.07 | -0.12 | -0.13 | -0.04 | 0.04 | -0.02 | -0.01 | 0.59 |
Annual figures · source: Financial Modeling Prep
ONCOTELIC THERAPEUTCS INC
No one on the platform currently holds OTLC.
No tracked institution reports a position in OTLC as of their last filing.
No one on the platform has traded OTLC yet.
| $28M |
| — |
| HBPCFHelix BioPharma Corp. | $1.71 | +0.00% | $131M | — |
| INNMFAmplia Therapeutics Limited | $0.12 | +43.75% | $59M | — |
Source: Financial Modeling Prep · peers by sector/industry
From Hospitality to Pharma: TechForce Robotics Expanding Its Robotics-as-a-Service Platform into Laboratory Automation $NGTF $OTLC https://ibn.fm/0lbFE
View on StockTwits ↗BioMedNewsBreaks — $OTLC Publishes Peer-Reviewed Validation of Deciparticle(TM) Platform https://ibn.fm/QTopP
View on StockTwits ↗$OTLC Breaking News | Oncotelic Therapeutics, Inc. (OTCQB: #OTLC) has published a peer-reviewed manuscript validating its innovative Deciparticle™ nanoparticle platform. This follows the development of Sapu003, an investigational intravenous formulation of everolimus currently in a Phase 1b clinical trial, marking a significant step forward in therapeutic advancements. https://youtu.be/YC-47svVwLM #TheBullRunShow #OTLC #Oncotelic #OTCQB #ArtificialIntelligence #Robotics #Manufacturing #Biotech #HealthTech #AIStocks #GrowthStocks #SmallCaps #TrendingStocks #StockMarket #MarketNews #Innovation
View on StockTwits ↗$OTLC Deciparticle platform The platform that will become a necessity to see any progress in many a pipeline.
View on StockTwits ↗$OTLC A parlay played with the joined technology of Roivant type companies and Oncotelic type companies makes all the difference and reduces the risk of failure to zero I ANTicipate some news forthcoming … who knows
View on StockTwits ↗$OTLC CEO purchased 255,000 shares at $0.04 for a total of $11,475. Trieu Vuong now owns 117,537,232 shares. https://ceo-buys.com
View on StockTwits ↗NetworkNewsBreaks – $OTLC Eyes Opportunity Through AI and Pharmaceutical Automation https://nnw.fm/jtydH
View on StockTwits ↗$OTLC and $RDGL A power packed $1-$2 punch Be prepared Bein.. repaired
View on StockTwits ↗The $410 Billion Drug Delivery Revolution: Why Drug Delivery May Be the Next Major Frontier in Oncology Innovation $OTLC https://ibn.fm/EImJf
View on StockTwits ↗$OTLC #OTLC Oncotelic Therapeutics, Inc. proudly unveils an innovative AI-powered GMP manufacturing services platform at the BIO International Convention 2026, paving the way for a transformative future in biopharmaceutical manufacturing. https://www.marketscreener.com/news/oncotelic-therapeutics-inc-launches-ai-powered-gmp-manufacturing-services-platform-at-bio-internat-ce7f5cddd081f525 #TheBullRunShow #Oncotelic #AIManufacturing #BIO2026 #Biopharma #Innovation @followers @highlight
View on StockTwits ↗$OTLC - The Platform leverages PDAOAI™, Oncotelic's proprietary AI architecture, to support: Electronic batch record generation and management AI-assisted manufacturing documentation GMP workflow digitization Quality and compliance support Manufacturing process monitoring Knowledge management and operational intelligence Integration with intelligent robotic systems through the Company's collaboration with TechForce C
View on StockTwits ↗$OTLC - Immunotherapies, Molecular Nanomedicine, and PDAOAI Drug Dev Platform. Advancing Cures Through Capital Efficient Partnerships https://www.oncotelic.com/#events
View on StockTwits ↗InvestorNewsBreaks – $OTLC Launches AI-Powered GMP Manufacturing Services Platform at BIO 2026 https://ibn.fm/6PlnZ
View on StockTwits ↗$OTLC — Oncotelic Launches AI-Powered GMP Manufacturing Services Platform at BIO International Convention 2026 https://finance.yahoo.com/healthcare/articles/oncotelic-launches-ai-powered-gmp-120000905.html
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.